IDH2 and central nervous system cancer: Relevant glioma diagnostic and prognostic biomarkers such as IDH mutation status, copy number aberrations including 1p/19q codeletions, MGMT promotor methylation status and differentiation of IDH-wildtype tumors into glioblastoma or indolent tumors, can all simultaneously be obtained from one analysis.